Henlius receives an IND approval for Its PD-L1-targeting ADC HLX43 in combination with anti-PD-1 mAb...

MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study...

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics

Fortitude Biomedicines launches with $13M in financing to advance novel antibody-based therapies for treatment of...

StarkAge Therapeutics announces research collaboration with Gustave Roussy to advance senolytic therapies in digestive cancers